Skip to main content
. 2023 Feb 28;251:115226. doi: 10.1016/j.ejmech.2023.115226

Fig. 4.

Fig. 4

Inhibition of the activity of the SARS-CoV-2 Mpro by korupensamine A (1a) and korupensamine B (1b) at increasing concentrations of the inhibitor. The enzyme activity is reduced by 50% at a korupensamine A (1a) concentration of 2.52 ± 0.14 μM (A) in comparison to that of korupensamine B (1b) at a concentration of 71.89 ± 0.49 μM (B) and that of the reference inhibitor GC376 [70] at a concentration of 0.88 ± 0.15 μM (C).